Pacific Biometrics Ends Negotiations with BestNet

SEATTLE--(BUSINESS WIRE)--Feb. 25, 2005--Pacific Biometrics, Inc. (OTC BB: PBME) has concluded discussions with BestNet Communications Corp. in relation to a proposed Stock Purchase Agreement and Asset Purchase and Management Agreement. The two companies have agreed not to pursue finalization of these agreements, previously outlined in a Letter of Intent.

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, cholesterol and lipid abnormalities, diabetes, obesity, metabolic syndrome, osteoporosis, and arthritis. The PBI laboratory is accredited by the College of American Pathologists and is one of only three U.S.-based laboratories approved and accredited by the Centers for Disease Control (CDC) as a member of the Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending technologies, including molecular diagnostic and noninvasive device technologies, relevant to its areas of specialty expertise.

For more information about Pacific Biometrics, visit the company's web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including but not limited to our strategic planning and business development plans, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission.